Evidence map›Paper›PMID 36595186›Full record

Observational studyJournal of cancer survivorship : research and practice2023

Quality of care and quality of life as experienced by patients with advanced cancer of a rare tumour type: results of the multicentre observational eQuiPe study.

Anouk van Oss, Saskia F A Duijts, Hanneke van Laarhoven, Evelien Kuip, Natasja J H Raijmakers, Linda Brom

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anouk van OssDepartment of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO box, 19079, 3501 DB, Utrecht, the Netherlands.
Saskia F A DuijtsDepartment of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO box, 19079, 3501 DB, Utrecht, the Netherlands.
Hanneke van LaarhovenCancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
Evelien KuipDepartment of Medical Oncology and Department of Anesthesiology, Pain and Palliative Care, Radboud University Medical Center, Nijmegen, the Netherlands.
Natasja J H RaijmakersDepartment of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO box, 19079, 3501 DB, Utrecht, the Netherlands.
Linda BromDepartment of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO box, 19079, 3501 DB, Utrecht, the Netherlands. l.brom@iknl.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with a rare cancer face difficulties during their disease trajectory, such as delayed diagnosis and lack of expert care. However, little is known about their perceived quality of care (QoC) and quality of life (QoL) in the advanced disease stage. We aimed to assess the QoC and QoL as experienced by patients with advanced rare cancers compared to patients with advanced common cancers.

methodsIn this cross-sectional study, baseline data of patients with advanced cancer from the multicentre, longitudinal, observational eQuipe study were analysed. Multivariable linear regression analyses were conducted to assess differences in experienced QoC (continuity of care, continuity of information, and satisfaction with care) and QoL (functioning, symptoms, overall QoL, and social wellbeing) between advanced rare and common cancer patients.

resultsOf the 1087 included patients, 106 (9.8%) had a rare cancer type. In comparison to patients with advanced common cancers, patients with advanced rare cancers experienced significantly lower continuity of care (77.8 vs. 71.1 respectively, p = 0.011) and social functioning (78.8 vs. 72.6 respectively, p = 0.012). No differences were found regarding continuity of information, satisfaction with care, overall QoL, and social wellbeing.

conclusionsPatients with advanced rare cancers experience less continuity of care, and the impact of the disease on social and family life seems higher compared to patients with advanced common cancers. IMPLICATIONS FOR CANCER SURVIVORS: To enhance the QoC and QoL of patients with advanced rare cancers, supportive care should mainly focus on improving continuity of care and patients' social functioning.

Indexed as

Cancer SurvivorsNeoplasmsCross-Sectional StudiesHumansQuality of Health CareQuality of LifeSurveys and QuestionnairesAdvanced cancerContinuity of carePalliative careQuality of careQuality of lifeRare cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.